Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19

There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitt, Bertram, Sutton, Nadia R., Wang, Zhong, Goonewardena, Sascha N., Holinstat, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923868/
https://www.ncbi.nlm.nih.gov/pubmed/33667455
http://dx.doi.org/10.1016/j.ejphar.2021.173988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923868/
https://www.ncbi.nlm.nih.gov/pubmed/33667455
http://dx.doi.org/10.1016/j.ejphar.2021.173988

Ejemplares similares